Irisin — Exercise-Induced Myokine

📖 Wiki Page

protein1297 wordssynced 2026-04-02

Irisin — Exercise-Induced Myokine

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Irisin — Exercise-Induced Myokine</th>
</tr>
<tr>
<td class="label">Precursor</td>
<td><a href="/genes/fndc5">FNDC5</a></td>
</tr>
<tr>
<td class="label">Length</td>
<td>112 amino acids (mature)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~12 kDa</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q8IZF6" target="_blank">Q8IZF6</a></td>
</tr>
<tr>
<td class="label">Source Tissue</td>
<td>Skeletal muscle</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>αVβ5 integrin</td>
</tr>
<tr>
<td class="label">Serum Concentration</td>
<td>10-100 ng/mL</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>~1 hour</td>
</tr>
<tr>
<td class="label">Induction</td>
<td>Exercise (2-3 fold increase)</td>
</tr>
<tr>
<td class="label">Related Diseases</td>
<td><a href="/diseases/alzheimers">Alzheimer's Disease</a>, <a href="/diseases/parkinsons-disease">Parkinson's Disease</a>, <a href="/diseases/als">ALS</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's Disease</a>, <a href="/wiki/depression" style="color:#ef9a9a">Depression</a>, <a href="/wiki/osteoporosis" style="color:#ef9a9a">Osteoporosis</a>, <a href="/wiki/sarcopenia" style="color:#ef9a9a">Sarcopenia</a>, <a href="/wiki/type-2-diabetes" style

...

Irisin — Exercise-Induced Myokine

Overview

Irisin is a cleaved, circulating form of the membrane protein <a href="/genes/fndc5">FNDC5</a> (Fibronectin Type III Domain Containing 5) that is primarily produced in skeletal muscle during exercise. Originally discovered in 2012 as a "exercise-induced hormone," irisin has since been shown to have profound effects on energy metabolism, brown adipose tissue thermogenesis, and critically, neuroprotection in models of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS)[@bostrm2012].

Irisin acts as a systemic mediator, conveying the benefits of exercise to distant tissues including the brain. This positions irisin as a compelling therapeutic target for neurodegenerative diseases where exercise has demonstrated beneficial effects but where pharmacological intervention could amplify or replicate these effects.

Discovery and Nomenclature

Historical Context

2012: Irisin was first described by Boström et al. in Nature[@bostrm2012]
Name origin: Named after Iris, the Greek goddess who crossed between heaven and earth
Rationale: Irisin crosses the blood-brain barrier and mediates exercise effects on the brain

Precursor Relationship

Irisin is generated through proteolytic cleavage of the full-length FNDC5 protein:

FNDC5 is expressed in skeletal muscle cells

The protein is processed by proteases (primarily ADAM17/TACE)

The extracellular domain is cleaved and released as irisin

Irisin enters circulation and reaches target tissues

Molecular Mechanism of Action

Receptor Binding

Irisin signals through multiple receptor pathways:

Primary Receptor: αVβ5 Integrin

Identification: Integrin αVβ5 was identified as the functional receptor for irisin[@irisin2020]
Signal transduction: Integrin engagement activates downstream signaling cascades
Tissue distribution: Expressed widely including in brain tissue

Alternative Mechanisms

Other integrins: αVβ3 and other integrins may contribute
Receptor-independent: Some effects may occur through non-classical mechanisms
Paracrine signaling: Local tissue production may have autocrine/paracrine effects

Intracellular Signaling Pathways

Mermaid diagram (expand to render)

Irisin activates multiple downstream signaling pathways:

| Pathway | Effect | Relevance to Neurodegeneration |
|---------|--------|-------------------------------|
| AMPK | Energy sensing, mitochondrial biogenesis | Metabolic support |
| ERK1/2 | Gene expression, cell survival | Neuroprotection |
| PI3K/Akt | Cell survival, protein synthesis | Anti-apoptotic |
| mTOR | Protein synthesis, autophagy | Synaptic plasticity |
| PGC-1alpha | Mitochondrial biogenesis | Energy metabolism |

Neuroprotective Effects

Alzheimer's Disease

Irisin has shown remarkable benefits in AD models:

Amyloid Pathology

Aβ reduction: Decreased amyloid-beta accumulation in hippocampus and cortex[@lourenco2019]
Plaque burden: Reduced amyloid plaque formation and burden
APP processing: Shifted APP processing toward non-amyloidogenic pathway

Tau Pathology

Phosphorylation: Reduced tau phosphorylation at multiple epitopes
Aggregation: Decreased tau oligomerization
NFT formation: Attenuated neurofibrillary tangle formation

Synaptic Function

LTP enhancement: Improved long-term potentiation in hippocampus
Synaptic markers: Preserved synaptophysin, PSD95 levels
Spine density: Maintained dendritic spine density

Cognitive Improvement

Memory: Enhanced spatial memory and learning in AD mice
Behavioral: Improved performance in Morris water maze, Y-maze
Neurogenesis: Increased hippocampal neurogenesis

Parkinson's Disease

Evidence for irisin's neuroprotective effects in PD:

Dopaminergic Neurons

TH preservation: Maintained tyrosine hydroxylase-positive neurons in substantia nigra[@liu2019]
Fiber density: Preserved striatal dopamine fiber density
Cell viability: Reduced dopaminergic neuron death

Alpha-Synuclein

Aggregation: Reduced α-synuclein aggregation
Toxicity: Decreased oligomeric α-synuclein toxicity
Clearance: Enhanced clearance mechanisms

Mitochondrial Function

Biogenesis: Increased PGC-1α expression and mitochondrial DNA
Complex I: Improved complex I activity
ROS: Reduced reactive oxygen species

Motor Function

Behavioral improvement: Enhanced performance in cylinder test, forelimb use
Locomotion: Improved horizontal and vertical activity

Amyotrophic Lateral Sclerosis (ALS)

In ALS models:

Motor Neuron Protection

Survival: Extended motor neuron survival
Degeneration: Reduced axonal degeneration
Neuromuscular junctions: Preserved NMJ integrity

Muscle Connection

Innervation: Maintained motor endplate innervation
Muscle function: Preserved muscle strength
Denervation: Delayed muscle denervation

Exercise and Irisin

Exercise-Induced Irisin Release

Exercise is the primary physiological stimulus for irisin release:

| Exercise Type | Irisin Increase | Duration |
|--------------|-----------------|----------|
| Aerobic (running) | 2-3 fold | 2-4 hours |
| Resistance training | 1.5-2 fold | 1-2 hours |
| High-intensity interval | 2-3 fold | Peak at 1 hour |
| Chronic exercise | Sustained elevation | Days to weeks |

Mechanisms of Induction

Exercise induces irisin through:

PGC-1α activation: Exercise increases PGC-1α in muscle

FNDC5 transcription: PGC-1α directly upregulates FNDC5 gene expression

Proteolytic processing: Enhanced ADAM17 activity increases cleavage

Secretion: Release into systemic circulation

Exercise Recommendations

For maximizing irisin-mediated neuroprotection:

Frequency: 3-5 sessions per week
Duration: 30-60 minutes per session
Intensity: Moderate to vigorous (65-85% HRmax)
Type: Aerobic exercise most effective; resistance training complementary

Therapeutic Approaches

Recombinant Protein Therapy

Advantages

Direct delivery of active protein
Well-characterized mechanism
Potential for CNS delivery

Challenges

Blood-brain barrier penetration
Short circulating half-life (~1 hour)
Manufacturing scalability
Dosing optimization

Gene Therapy

Approaches

AAV-FNDC5: Adeno-associated virus-mediated FNDC5 expression
mRNA delivery: Lipid nanoparticle mRNA encoding FNDC5
CRISPR activation: Epigenetic upregulation of endogenous FNDC5

Status

Preclinical studies ongoing
AAV delivery to brain demonstrated safety
Efficacy shown in AD mouse models

Small Molecule Agonists

| Target | Compound Class | Status |
|--------|---------------|--------|
| PGC-1α | PPAR agonists | Research |
| AMPK | Metformin, AICAR | Research |
| FNDC5 transcription | HDAC inhibitors | Research |
| Irisin mimetics | Peptide analogs | Research |

Exercise Mimetics

Compounds that replicate exercise effects:

PGC-1α agonists: Direct activation of PGC-1α
AMPK activators: Pharmacological AMPK activation
SIRT1 activators: Resveratrol and analogs

Clinical Translation

Biomarker Development

Irisin as a biomarker:

Serum levels: Readily measurable by ELISA
Exercise correlation: Correlates with exercise intensity
Disease association: Altered levels in AD, PD, diabetes
Therapeutic monitoring: Potential treatment response marker

Clinical Trials

Current status:

Exercise intervention trials measuring irisin
Safety studies for recombinant irisin
Phase I trials anticipated for irisin analogs

Challenges

| Challenge | Impact | Mitigation Strategy |
|-----------|--------|-------------------|
| BBB penetration | Limited brain delivery | Intranasal, focused ultrasound |
| Half-life | Short duration | PEGylation, fusion proteins |
| Dosing | Unknown optimal dose | Biomarker-guided dosing |
| Specificity | Off-target effects | Targeted delivery |

Cross-Links

<a href="/genes/fndc5">FNDC5</a> — Precursor gene
<a href="/mechanisms/pgc1-alpha-neurodegeneration">PGC-1α</a> — Transcriptional regulator
<a href="/mechanisms/ampk-signaling">AMPK</a> — Energy sensor
<a href="/mechanisms/bdnf-neuroprotection">BDNF</a> — Neurotrophic factor

[Mitochondrial Biogenesis](/mechanisms/mitochondrial-dysfunction-neurodegeneration)
[Synaptic Plasticity](/mechanisms/long-term-potentiation)
[Neuroinflammation](/mechanisms/neuroinflammation)
[Autophagy in Neurodegeneration](/mechanisms/autophagy-lysosome-neurodegeneration)

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[ALS](/diseases/amyotrophic-lateral-sclerosis)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Boström et al., A PGC1-α-dependent myokine that drives brown-fat-like thermogenesis (2012) (2012)](https://doi.org/10.1038/nature10753)

[Unknown, Irisin receptor identification (Works et 2020) (2020)](https://doi.org/10.1038/s41586-020-2642-9)

[Lourenco et al., Irisin reduces amyloid-beta (2019) (2019)](https://doi.org/10.1093/brain/awz291)

[Liu et al., Irisin protects dopaminergic neurons (2019) (2019)](https://doi.org/10.1007/s12035-019-1580-6)

[Wrann et al., Exercise induces FNDC5 expression (2013) (2013)](https://doi.org/10.1152/japplphysiol.00028.2013)

📖 View canonical wiki page →

Irisin — Exercise-Induced Myokine

Irisin — Exercise-Induced Myokine

Irisin — Exercise-Induced Myokine

Irisin — Exercise-Induced Myokine

Overview

Discovery and Nomenclature

Historical Context

Precursor Relationship

Molecular Mechanism of Action

Receptor Binding

Primary Receptor: αVβ5 Integrin

Alternative Mechanisms

Intracellular Signaling Pathways

Neuroprotective Effects

Alzheimer's Disease

Amyloid Pathology

Tau Pathology

Synaptic Function

Cognitive Improvement

Parkinson's Disease

Dopaminergic Neurons

Alpha-Synuclein

Mitochondrial Function

Motor Function

Amyotrophic Lateral Sclerosis (ALS)

Motor Neuron Protection

Muscle Connection

Exercise and Irisin

Exercise-Induced Irisin Release

Mechanisms of Induction

Exercise Recommendations

Therapeutic Approaches

Recombinant Protein Therapy

Advantages

Challenges

Gene Therapy

Approaches

Status

Small Molecule Agonists

Exercise Mimetics

Clinical Translation

Biomarker Development

Clinical Trials

Challenges

Cross-Links

Related Genes and Proteins

Related Mechanisms

Related Diseases

See Also

External Links

References